News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALLR new 52 week low
Saw the volume this morning. They just did a split and thjey're already back under the $. A lot of selling here, no doubt.
No risk no reward... 
ALLR new 52 week low
ALLR new 52 week low
Boston (May 14, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024.
“The start of 2024 has been a pivotal period for Allarity Therapeutics, marked by significant achievements across financial, regulatory, and clinical areas,” remarked Thomas Jensen, CEO of Allarity Therapeutics. “Our trials of stenoparib in advanced, recurrent ovarian cancer have yielded encouraging proof of concept data, which further boosted our optimism for the future of this novel PARP inhibitor. Additionally, we’ve seen several developments that we believe may strengthen our investment case. Our capital structure has been simplified, and we have raised new equity, so we are now on track to fully comply with Nasdaq’s listing requirements and find ourselves in a better position to steer clear of less favorable future financing arrangements. Reflecting this new strengthened financial position, we have requested the SEC to withdraw our Form S-1 filed last October. With a strategic focus now solely on stenoparib, we can use all our managerial resources to advance this promising asset toward regulatory approval.”
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved
- On Track to Regain Compliance with All Nasdaq Listing Requirements
- No Variable Priced Securities are Outstanding
$ALLR more massive dilution from this scam how bullish.
Patience there's a nice bounce coming from .09 to 11
$ALLR atm will be off soon. We filed the Prior Prospectus to register the offer and sale of our common stock, par value $0.0001 per share, from time to time pursuant to the terms of that certain At-The-Market Issuance Sales Agreement (the “Sales Agreement”), between Ascendiant Capital Markets, LLC (the “Sales Agent”) and us. Prior to the date of this prospectus supplement, we were subject to General Instruction I.B.6 of Form S-3 as a result of our public float being less than $75.0 million, which limited the maximum amount of common stock we could sell under the Sales Agreement to the amount set forth in the Prior Prospectus (up to $18,000,000). On May 2, 2024, our public float increased above $75.0 million and, as a result, we are not subject to the limitations contained in General Instruction I.B.6 of Form S-3 as of the date of this prospectus supplement.
On May 6, 2024, we amended the Sales Agreement to, among other things, increase the total amount of common stock that we may offer and sell under the sales agreement to $20,000,000 (which amount includes shares we have already sold pursuant to the Sales Agreement prior to the date of this prospectus supplement), subject to certain limitations in the Sales Agreement, as amended. As of May 2, 2024, we have sold an aggregate of 10,835,422 shares of our common stock pursuant to the Sales Agreement for gross proceeds of 16,054,081 (the “Gross Proceeds”).
Trading at 4.5 cents on a pre rollback basis. Geez.
ALLR new 52 week low
Shorts win again
No mercy for longs. Either from shorts or from management.
lol looks like it’s gonna finish in the RED
ALLR new 52 week low
You’re good at translating corporate speak
ALLR new 52 lo
ALLR new 52 lo
"In addition, the company has entered into negotiations with key stakeholders, including warrant holders, to adjust the terms and conditions to make future capital raising more amenable, as well as negotiations to reduce other major liabilities. Finally, the Company has already started raising new equity by utilizing its existing ATM and expects to take further action so Allarity can meet the $2,500,000 equity requirement on the May 14, 2024 target date."
They plan on CONTINUING TO DUMP SHARES on the open market and DILUTING their shareholders with no end in sight.
"Our goal is to ensure that we can continue our development of stenoparib, strongly encouraged by the significant early data we have received so far from our ongoing monotherapy trial in advanced ovarian cancer."
In other words stenoparib is still not ready for phase 3. They are going to have to chemically modify it to try to improve it which means repeating phase 1 and phase 2 trials. They are going to need a A LOT more time and money and there is no guarantee at all that they can get it modified to the point it needs to be at.
This is a TOXIC investment. If there happens to be a pump, sell for what you can and get out. They are just going to continue with the reverse splits followed by dilution for the foreseeable future as they have no revenue, no product, and thomas jackass jensen needs to collect his handsome salary.
Nothing to be bullish about here. This company is now a one trick pony. If stenoparib fails they are done. I'm thinking if stenoparib was doing as good as their last press release indicated then the price would be appreciating. Tread carefully as investing in this company is a gamble and I personally do not trust management.
|
Followers
|
13
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
396
|
|
Created
|
12/16/22
|
Type
|
Free
|
| Moderators | |||
